• HCW Biologics is trading 6% down at $2.35 in after-hours trading, extending a sharp multi-day slide.
  • The move follows the company's announcement yesterday, July 23, 2026, of a request for a Type B pre-IND FDA meeting for its investigational lead candidate, HCW11-018b, a tetravalent T-cell engager.
  • HCW Biologics is targeting to initiate clinical trials for HCW11-018b in the first half of 2027.